Videos

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, describes the current state of antimicrobial stewardship efforts.

Rasheeta Chandler, PhD, RN, APRN-BC, FNP-BC, FAANP, FAAN, explains the need to incorporate women at-risk for or living with HIV into the decision-making process if we are to end the epidemic.

Max Brito, MD, MPH, remarks on the underrepresentation of transgender women in HIV and other sexual health research.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses his journey from social media skeptic to “Twitter convert.”

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses some of the broader themes in ID over the course of 2019.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses noteworthy infectious disease papers published in 2019.

Daniel B. Chastain, PharmD, BCIDP, AAHIVP, discusses a retrospective study of errors occurring in the treatment of patients with HIV.

Jason Tokumoto, MD, discusses how occupying the role of both patient and physician can provide a human perspective on HIV care.

Brenna Hughes, MD, MSc, explains why we need more effective options for congenital CMV.

Pamela Gorman, RN, ACRN, discusses the importance of clinics having team members who come from the community patients are being recruited from.

Jason Tokumoto, MD, discusses recent developments in HIV treatment and prevention, focusing on the impact of “U=U.”

Jason Schafer, PharmD, MPH, BCPS AQ-ID, discusses upcoming long-acting therapies for HIV.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the December issue.

Brenna Hughes, MD, MSc, discusses the hypothesis that CMV hyperimmune globulin could have an effect on stopping congenital infections and results of a trial.

Gregory Felzien, MD, AAHIVS, highlights “clinic champions” who help move patient care forward while facing external constraints.

Carlos del Rio, MD, discusses advances in long-acting antiretrovirals and the costs associated with HIV therapies.

Representatives from the AIDS Care Group discuss the racial disparities that exist in the HIV/AIDS care continuum for women of color, as well as how a peer engagement and retention program can help.

In the December issue of Contagion®, Carlos del Rio, MD, Debra Goff, PharmD, and Paul Sax, MD, discuss the benefit of infectious disease clinicians using Twitter.

Timothy Ray Brown, also known as the "Berlin Patient" discusses why it's important to push out the message that U=U.

Pamela Gorman, RN, ACRN, discusses how electronic health data and coordinated outreach can be combined to increase retention in care.

Jennifer Cocohoba, PharmD, summarizes her ANAC 2019 presentation on polypharmacy and how it affects people living with HIV.

In an interview at ANAC 2019, Shameka L. Cody, PhD, AGNP-C, discusses the impact of cognitive training on quality of life outcomes for people with HIV-associated neurocognitive disorder.

Timothy Ray Brown, formerly known as the “Berlin Patient” explains why it is important for providers to form relationships with patients and avoid stigma and judgment.

Brian Minalga, MSW, discusses research on the historical exclusion of women in HIV cure-related research.

Julie Zuñiga, PhD, RN, shares findings from her research on self-management of the dual diagnosis of HIV and diabetes.

Timothy Ray Brown is the first person to ever be cured of HIV. He discusses his decision to no longer remain anonymous and why he shares his story with the world.

A new review in The Lancet HIV discusses the next generation of HIV prevention, called PrEP 2.0.

Mark Riddle, MD, DrPH, speaks about his research on travelers’ diarrhea and multidrug resistance at ACG 2019.